One of the APF’s earliest efforts was testifying before Congress in support of the Orphan Drug Act (1983). Panhematin, which remains the only specific treatment for acute porphyria available in the United States, was the first drug to be approved under the ODA. The APF continues to be very active in the Treatments, testing, and research for Porphyrias.
Since then, we have published materials...